PR Newswire
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
📈
AI Sentiment
Highly Positive
9/10
Latest updates and market news for HURA
AI Sentiment
Highly Positive
9/10
Share this news page